DDInter173 DDInter1376
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells. It is produced by recombinant DNA technology in a murine cell (NS0) expression system. Belimumab was first approved by the FDA on March 9, 2011, making it the newest drug to be approved for the treatment of SLE in more than 50 years. It is currently used to treat SLE and lupus nephritis.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Belimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Belimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Belimumab may lead to a major life threatening interaction when taken with Tofacitinib
Belimumab may lead to a major life threatening interaction when taken with Natalizumab